samira shabani; Massoud houshnamnd; tayebeh majidizade; samira sheibania
Volume 26, Issue 1 , 2024
Abstract
A new worldwide pandemic of coronavirus disease 2019 (COVID-19) has resulted in a healthcare crisis with high mortality and morbidity. Presently, several drugs are under accelerated research without established efficacy and are being used to treat COVID-19 patients either as unapproved drug use or as ...
Read More
A new worldwide pandemic of coronavirus disease 2019 (COVID-19) has resulted in a healthcare crisis with high mortality and morbidity. Presently, several drugs are under accelerated research without established efficacy and are being used to treat COVID-19 patients either as unapproved drug use or as clinical trials. To optimally use the drugs, several factors, such as the gene effects, drug interactions, and drug toxicity, should be considered. Genetic polymorphisms are a type of genetic diversity within a populations gene pool that constitute the basis of pharmacokinetics, which causes alteration in the drug function and response. Since there was a limited time to check individual pharmacogenomics markers, it seems population pharmacogenomics tests could be helpful in expecting drug treatment failure in COVID-19 patients. We genotyped and investigated allele frequencies of 33 SNPs located on 10 pharmacogenes from 150 healthy individual samples.A total of 32 potential pharmacogenomics variants relevant to COVID-19 treatment were identified in the Iranian population. Considering them in patients' pharmacotherapy could influence the treatment optimization and reduce severity of adverse effects.
Effat Asdadollahpour; Maryam Daneshpour; Bahareh Sedaghati Khayat; Arsalan Hashemiaghdam; Mahsa Mohammad Amoli; Mostafa Qorbani; Farideh Razi
Volume 19, Issue 1 , January 2017, , Pages 1-6
Abstract
Background: Myosin heavy chain 9 (MYH9) gene polymorphisms have been implicated in different types of renal disease, as well as in nephropathy attributed to type 2 diabetes mellitus.Objectives: This study sought to analyze the association of MYH9 gene polymorphism (rs4821481) with diabetic nephropathy ...
Read More
Background: Myosin heavy chain 9 (MYH9) gene polymorphisms have been implicated in different types of renal disease, as well as in nephropathy attributed to type 2 diabetes mellitus.Objectives: This study sought to analyze the association of MYH9 gene polymorphism (rs4821481) with diabetic nephropathy (DN), urine albumin excretion value, and glomerular filtration rate (GFR) in an Iranian diabetic population.Methods: This case-control study included 201 diabetic patients with and without DN, who were referred to the diabetes and metabolic center, Tehran, Iran. The allele and genotype frequencies of rs4821481 were determined using ARMS-polymerase chain reaction (ARMS-PCR). In both groups, blood levels of fasting glucose, HbA1c, urea, creatinine, uric acid, and lipids, as well as urine albumin and creatinine, were measured and GFR was calculated.Results: Patients who carried the rs4821481 polymorphism had significantly higher urinary excretion of albumin (P < 0.05) and insignificantly lower GFR values (P = 0.08). The frequency of rs4821481 SNP was 22.8% in patients without DN versus 28% in the DN group, which was not statistically significant. Only 2% and 3% of patients without DN and with DN, respectively, had two copies of the C allele. No significant association was found between the rs4821481 polymorphism and DN (OR [95% CI] 1.56 [0.79 - 3.08], P =0.19).Conclusions: Although we found an association between MYH9 gene polymorphism and urinary albumin excretion, the results did not show a significant association between MYH9 polymorphism (rs4821481) and risk of DN in Iranian diabetic patients.
